Analysts expect Upstream Bio to report Q3 2026 revenue of approximately $0.53 million and a net loss of $0.73 per share, while the stock currently trades at $3.23 against a $29.83 price target.

The central focus for investors is the updated timeline for initiating pivotal Phase 3 trials for the company's lead candidate, verekitug, in severe asthma and chronic rhinosinusitis with nasal polyps.

Following positive Phase 2 VALIANT results, management is transitioning toward late-stage development with Phase 3 initiations planned for the first quarter of 2027. Investors will also scrutinize the cash runway and R&D burn rate to ensure the firm can fund these extensive clinical programs through completion.